NAMS — NewAmsterdam Pharma Co N.V.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1936258 ·
Last close
$21.26
Market Cap
$2.49B
52W High
$42.21
52W Low
$20.93
ADV30
1,692,320
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 3,701,000 | — | -64,864,000 | -64,135,000 | 704,452,000 | 424,151,000 | 73,030,000 |
| Mar 2026 | 3,040,000 | — | -58,420,000 | -48,441,000 | 732,643,000 | 457,607,000 | 67,421,000 |
| Dec 2025 | 32,000 | — | -65,980,000 | -74,923,000 | 769,284,000 | 490,002,000 | 85,853,000 |
| Sep 2025 | 348,000 | — | -55,143,000 | -72,005,000 | 786,427,000 | 538,407,000 | 58,357,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-143,462,000
Investing CF
$-34,906,000
Financing CF
$41,682,000
CapEx
$-260,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.71
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-874,966,000
Inventory
—
Receivables
$5,345,000
ST Investments
$209,703,000
EBIT TTM
$-244,407,000
Pretax Income TTM
$-259,504,000
Interest Exp TTM
—
Analysts
15
Yahoo Snapshot (yfinance, live)
Total Revenue
$7,121,000
EBITDA
$-244,163,008
Free Cash Flow
$-45,358,376
Enterprise Value
$2,091,675,392
Total Cash
$633,854,016
Total Debt
$82,000
Shares Out
116,903,979
Trailing EPS
$-2.16
Book Value
$5.37
ROE
-36.8%
ROA
-20.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 22,503,000 | -225,683,000 | -203,819,000 | 769,284,000 | 85,853,000 | 683,431,000 | -147,783,000 |
| Dec 2024 | 45,563,000 | -176,289,000 | -241,598,000 | 864,620,000 | 107,120,000 | 757,500,000 | -158,564,000 |
| Dec 2023 | 14,090,000 | -182,967,000 | -176,937,000 | 347,097,000 | 58,704,000 | 288,393,000 | -141,218,000 |
| Dec 2022 | 102,694,000 | -3,557,000 | -22,634,000 | 478,497,000 | 48,431,000 | 430,066,000 | 10,665,000 |
TTM Snapshot
Revenues TTM
$22,565,000
NetIncome TTM
$-212,733,000
OpCashFlow TTM
—
Assets (Latest)
$732,643,000
Forward EPS
$-1.57
Max Pain — expiry 2027-01-15
max pain strike: $25.00 · spot: $21.26 · call oi: 2,145 · put oi: 7,261
Expected Move to 2027-01-15:
±$9.11
(42.85%) —
implied range
$12.15 –
$30.37
· ATM straddle on $22.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LQDA | Liquidia Corp | $2.51B | $28.02 | — |
| SUPN | SUPERNUS PHARMACEUTICALS, INC. | $2.45B | $42.14 | — |
| MBX | MBX Biosciences, Inc. | $2.56B | $53.25 | — |
| HCM | HUTCHMED (China) Ltd | $2.38B | $13.67 | — |
| IRON | Disc Medicine, Inc. | $2.33B | $60.77 | — |
News headlines (Yahoo Finance, 1h cache)
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-10-02 20:01 · Yahoo
NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer’s Disease
2026-09-29 12:00 · Yahoo
NewAmsterdam Pharma (NAMS) Wins EU Approvals. Can Cholesterol Pills Drive Royalties?
2026-09-23 01:20 · Yahoo
NewAmsterdam Pharma and Menarini Group Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
2026-09-21 13:00 · Yahoo
NewAmsterdam Pharma (NAMS) Stock Looks Above Fair Value After Its 139% Run
2026-09-20 04:18 · Yahoo
NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Comb
2026-07-24 12:00 · Yahoo
Cambrex, Snapdragon Chemistry, and Q1 Scientific Recognized for Innovation and Sustainability in Pharma
2026-07-07 12:00 · Yahoo
Group 1 Automotive and 4 More Stocks See Action From Activist Investors
2026-10-02 22:02 · Yahoo
Aclaris (ACRS) Soars 6.0%: Is Further Upside Left in the Stock?
2026-09-15 12:47 · Yahoo
How Novartis' Double-Stacked Failures Reverberated Through Biopharma
2026-09-08 20:26 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.